SG11202003974XA - Macrocyclic compound serving as weel inhibitor and applications thereof - Google Patents
Macrocyclic compound serving as weel inhibitor and applications thereofInfo
- Publication number
- SG11202003974XA SG11202003974XA SG11202003974XA SG11202003974XA SG11202003974XA SG 11202003974X A SG11202003974X A SG 11202003974XA SG 11202003974X A SG11202003974X A SG 11202003974XA SG 11202003974X A SG11202003974X A SG 11202003974XA SG 11202003974X A SG11202003974X A SG 11202003974XA
- Authority
- SG
- Singapore
- Prior art keywords
- applications
- macrocyclic compound
- compound serving
- weel inhibitor
- weel
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711058653 | 2017-11-01 | ||
| PCT/CN2018/112909 WO2019085933A1 (fr) | 2017-11-01 | 2018-10-31 | Composé macrocyclique servant d'inhibiteur de wee1 et ses applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003974XA true SG11202003974XA (en) | 2020-05-28 |
Family
ID=66332843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003974XA SG11202003974XA (en) | 2017-11-01 | 2018-10-31 | Macrocyclic compound serving as weel inhibitor and applications thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11613545B2 (fr) |
| EP (1) | EP3712150B1 (fr) |
| JP (1) | JP7290638B2 (fr) |
| CN (2) | CN111344290B (fr) |
| AU (1) | AU2018361010B2 (fr) |
| BR (1) | BR112020008664A8 (fr) |
| CA (1) | CA3080842A1 (fr) |
| IL (1) | IL274357B2 (fr) |
| SG (1) | SG11202003974XA (fr) |
| WO (1) | WO2019085933A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623615B (zh) * | 2017-03-23 | 2022-12-13 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
| EP3875460A4 (fr) * | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Dérivé de pyrimidopyrazolone en tant qu'inhibiteur de wee1 et son utilisation |
| US20220220120A1 (en) * | 2019-04-30 | 2022-07-14 | Shijiazhuang Sagacity New Drug Development Co., Ltd | Crystal form of wee1 inhibitor compound and use thereof |
| CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| MX2022007624A (es) * | 2019-12-20 | 2022-08-16 | Recurium Ip Holdings Llc | Combinaciones. |
| EP4069234A4 (fr) * | 2019-12-20 | 2024-01-03 | Recurium IP Holdings, LLC | Associations |
| CN115197221B (zh) * | 2021-04-02 | 2024-05-24 | 轩竹(北京)医药科技有限公司 | 二氢吡唑并嘧啶酮类大环衍生物及其用途 |
| TW202328142A (zh) * | 2021-09-18 | 2023-07-16 | 香港商優領醫藥科技(香港)有限公司 | 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用 |
| WO2023155892A1 (fr) * | 2022-02-18 | 2023-08-24 | Insilico Medicine Ip Limited | Inhibiteurs de kinase (pkmyt1) inhibitrice de cdc2 spécifique de la tyrosine et de la thréonine associés à la membrane et leurs utilisations |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| EP2155752B1 (fr) | 2007-04-25 | 2018-09-19 | Merck Sharp & Dohme Corp. | Polymorphe de dérivé de dihydropyrazolopyrimidinone comme inhibiteur de la kinase weel |
| WO2009054332A1 (fr) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | Dérivé de dihydropyrazolopyrimidinone substitué par pyridone |
| CA2745970A1 (fr) | 2008-12-12 | 2010-06-17 | Msd K.K. | Derive de dihydropyrimidopyrimidine |
| PT2477628E (pt) | 2009-09-15 | 2014-11-25 | Merck Sharp & Dohme | Preparação de formas de hemihidrato cristalino de dihidropirazolopirimidinona |
| WO2011049988A2 (fr) | 2009-10-20 | 2011-04-28 | Eiger Biopharmaceuticals, Inc. | Indazoles pour traiter une infection par le virus flaviviridae |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2013012681A1 (fr) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Inhibiteurs tricycliques de kinases utiles pour le traitement des maladies prolifératives |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| US9181239B2 (en) | 2011-10-20 | 2015-11-10 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| US9718821B2 (en) | 2012-02-23 | 2017-08-01 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| CN105452246A (zh) | 2013-06-06 | 2016-03-30 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | Zeste增强子同源物2的抑制剂 |
| WO2015019037A1 (fr) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Composés pharmaceutiques |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| CA3003737C (fr) | 2015-11-01 | 2021-09-14 | The Regents Of The University Of Colorado, A Body Corporate | Inhibiteurs de la kinase wee1 et leurs procedes de fabrication et d'uti lisation |
| CN108623615B (zh) * | 2017-03-23 | 2022-12-13 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
| EP3875460A4 (fr) * | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Dérivé de pyrimidopyrazolone en tant qu'inhibiteur de wee1 et son utilisation |
-
2018
- 2018-10-31 AU AU2018361010A patent/AU2018361010B2/en active Active
- 2018-10-31 US US16/759,769 patent/US11613545B2/en active Active
- 2018-10-31 WO PCT/CN2018/112909 patent/WO2019085933A1/fr active Application Filing
- 2018-10-31 EP EP18874492.4A patent/EP3712150B1/fr active Active
- 2018-10-31 CN CN201880071103.3A patent/CN111344290B/zh active Active
- 2018-10-31 BR BR112020008664A patent/BR112020008664A8/pt unknown
- 2018-10-31 CN CN202311487748.4A patent/CN117534673A/zh active Pending
- 2018-10-31 CA CA3080842A patent/CA3080842A1/fr active Pending
- 2018-10-31 SG SG11202003974XA patent/SG11202003974XA/en unknown
- 2018-10-31 JP JP2020524447A patent/JP7290638B2/ja active Active
-
2020
- 2020-04-30 IL IL274357A patent/IL274357B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021501191A (ja) | 2021-01-14 |
| AU2018361010B2 (en) | 2023-01-12 |
| RU2020117443A3 (fr) | 2021-12-01 |
| CN117534673A (zh) | 2024-02-09 |
| CN111344290A (zh) | 2020-06-26 |
| RU2020117443A (ru) | 2021-12-01 |
| EP3712150B1 (fr) | 2024-06-12 |
| US11613545B2 (en) | 2023-03-28 |
| US20200325145A1 (en) | 2020-10-15 |
| IL274357B1 (en) | 2023-01-01 |
| AU2018361010A1 (en) | 2020-06-11 |
| BR112020008664A2 (pt) | 2020-10-27 |
| EP3712150A4 (fr) | 2021-03-10 |
| EP3712150A1 (fr) | 2020-09-23 |
| BR112020008664A8 (pt) | 2023-01-17 |
| CA3080842A1 (fr) | 2019-05-09 |
| CN111344290B (zh) | 2023-12-01 |
| WO2019085933A1 (fr) | 2019-05-09 |
| IL274357A (en) | 2020-06-30 |
| IL274357B2 (en) | 2023-05-01 |
| JP7290638B2 (ja) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202003974XA (en) | Macrocyclic compound serving as weel inhibitor and applications thereof | |
| IL271964A (en) | Macrocyclic compounds and their uses | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| IL274006A (en) | Compounds that suppress factor Xia or kallikrein and preparations containing them | |
| EP3389658A4 (fr) | Inhibiteurs de glycosidase et leurs utilisations | |
| IL269711A (en) | ASK1 inhibitory compounds and their uses | |
| EP3331530A4 (fr) | Inhibiteurs de mthfd2 et utilisation desdits inhibiteurs | |
| EP3281942A4 (fr) | Inhibiteur de ss-lactamase et son application | |
| IL288991A (en) | A macrocyclic compound and its uses | |
| EP3336091A4 (fr) | Inhibiteur d'irak4 et son utilisation | |
| ZA201906135B (en) | Tri-cycle compound and applications thereof | |
| EP3336090A4 (fr) | Inhibiteur de l'irak4 et son utilisation | |
| EP3700934A4 (fr) | Composés et utilisations de ces composés | |
| EP3144309A4 (fr) | Composé tricyclique et inhibiteur de jak | |
| IL255219A0 (en) | pde10 suppressor compounds, preparations containing them and their uses | |
| EP3383877A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3342765A4 (fr) | Inhibiteur de cathepsine k et son application | |
| EP3247357A4 (fr) | Composés d'isoergoline et leurs utilisations | |
| EP3640242A4 (fr) | Composé inhibiteur de rock et utilisations correspondantes | |
| EP3733660A4 (fr) | Composé n-alkyl-n-cyanoalkylbenzamide et utilisation associée | |
| EP3630083A4 (fr) | Composés de diméthyl-nonatétraényl-triméthyl-cyclohexyle et leurs utilisations | |
| EP3442533A4 (fr) | Composés inhibiteurs de tg2 et utilisations de ces derniers | |
| EP3279196A4 (fr) | Composé tétrazolinone et son utilisation | |
| GB201602572D0 (en) | New compound and uses |